scholarly article | Q13442814 |
P819 | ADS bibcode | 2017PLoSO..1271280K |
P356 | DOI | 10.1371/JOURNAL.PONE.0171280 |
P932 | PMC publication ID | 5287480 |
P698 | PubMed publication ID | 28146588 |
P50 | author | Hyo Sup Shim | Q59690264 |
P2093 | author name string | Eun Kyung Kim | |
Chang Young Lee | |||
Kyung A Kim | |||
P2860 | cites work | The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. | Q33770932 |
Lung cancer: intragenic ERBB2 kinase mutations in tumours | Q34354426 | ||
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. | Q34536780 | ||
Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis | Q36072192 | ||
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation | Q36322762 | ||
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. | Q36423790 | ||
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas | Q36644476 | ||
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. | Q37398636 | ||
Targeting HER2 in the treatment of non-small cell lung cancer | Q38324334 | ||
Effect of HER2/neu expression on survival in non-small-cell lung cancer | Q47289478 | ||
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. | Q50775865 | ||
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. | Q27824805 | ||
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial | Q27824810 | ||
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. | Q27851719 | ||
Cancer statistics, 2015 | Q27860576 | ||
Untangling the ErbB signalling network | Q27860884 | ||
Comprehensive molecular profiling of lung adenocarcinoma | Q28244995 | ||
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives | Q28289431 | ||
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. | Q33359693 | ||
Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients. | Q51544956 | ||
HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation. | Q52996871 | ||
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. | Q53381227 | ||
Correlation of HER-2/Neu protein expression and HER2 gene amplification with clinical morphological parameters of nonsmall cell lung cancer. | Q54313117 | ||
HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. | Q54336136 | ||
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 | ||
HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry | Q79078748 | ||
HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin | Q79289949 | ||
Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains | Q82448154 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | adenocarcinoma | Q356033 |
P304 | page(s) | e0171280 | |
P577 | publication date | 2017-02-01 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | The frequency and clinical impact of HER2 alterations in lung adenocarcinoma | |
P478 | volume | 12 |
Q55396331 | Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma. |
Q90091776 | Autophagy-related Proteins as a Prognostic Factor of Patients With Colorectal Cancer |
Q92859970 | Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma |
Q47261688 | Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy. |
Q90513170 | Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer |
Q55123690 | Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer. |
Q54962247 | Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. |
Q64084185 | The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation |
Q59813207 | The effect of piperlongumine on endothelial and lung adenocarcinoma cells with regulated expression of profilin-1 |
Q46915997 | Understanding and targeting resistance mechanisms in NSCLC. |
Search more.